静脉利多卡因预防咳嗽:随机对照试验的系统综述与荟萃分析
该系统综述与荟萃分析检索至2017年1月1日,纳入成人20项试验(n=3062)和儿童5项试验(n=445),比较静脉利多卡因与安慰剂预防咳嗽。利多卡因0.5-2 mg·kg可剂量依赖性降低成人及儿童插管、拔管或阿片诱导的咳嗽发生率,成人NNT从8降至3;高危患者伤害风险未知。
要点
- 静脉利多卡因0.5-2 mg·kg可预防成人及儿童插管、拔管或阿片诱导的咳嗽。
- 成人数据呈剂量依赖性,0.5 mg·kg时NNT为8,2 mg·kg时NNT为3。
- 高危患者伤害风险未知,不良反应报告稀疏。
核心结论
- 在0.5-2 mg·kg范围内,静脉利多卡因剂量依赖性预防成人及儿童插管、拔管和阿片诱导的咳嗽,NNT范围为8至3。
- 高危患者的伤害风险仍未知。
研究设计与样本
- 系统综述与荟萃分析,检索电子数据库至2017年1月1日,纳入比较静脉利多卡因与安慰剂预防手术患者咳嗽的随机试验。
- 共纳入成人20项试验(n=3062)和儿童5项试验(n=445),测试利多卡因0.5-2 mg·kg。
主要发现
- 利多卡因与安慰剂相比,在成人和儿童中降低咳嗽发生率,与剂量和咳嗽病因无关。
- 成人数据提示剂量反应性:0.5 mg·kg时RR为0.66(0.50-0.88),NNT为8(5.4-14.3)。
- 1 mg·kg时RR为0.58(0.49-0.69),NNT为7(4.6-8.9)。
- 1.5 mg·kg时RR为0.44(0.33-0.58),NNT为5(3.3-5.2)。
- 2 mg·kg时RR为0.39(0.24-0.62),NNT为3(2.0-3.4)。
临床怎么用
- 对于成人及儿童,可考虑静脉利多卡因0.5-2 mg·kg预防插管、拔管或阿片诱导的咳嗽,剂量越高NNT越低。
- 高危患者使用前需权衡未知的伤害风险。
局限性
- 不良反应报告稀疏,高危患者伤害风险未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It remains unclear to what extent intravenous lidocaine prevents cough and whether there is dose-responsiveness and risk of harm. METHODS: We searched electronic databases to January 1, 2017 for randomized trials comparing intravenous lidocaine with placebo for the prevention of cough in surgical patients. Primary outcome was the incidence of cough. Data were analyzed using a random-effects model and were expressed as risk ratio (RR) and number needed to treat (NNT) with 95% confidence interval. RESULTS: In 20 trials in adults (n = 3062) and 5 trials in children (n = 445), intravenous lidocaine 0.5-2 mg·kg was tested for the prevention of intubation-, extubation-, or opioid-induced cough. Twenty-two trials included only American Society of Anesthesiologists I or II patients; 3 trials (n = 99) also included American Society of Anesthesiologists III patients. Lidocaine was associated with a lower incidence of cough compared to placebo in adults and children, irrespective of dosage and cough etiology. Data from adults suggested dose-responsiveness; with 0.5 mg·kg, RR was 0.66 (0.50-0.88) and NNT was 8 (5.4-14.3); with 1 mg·kg, RR was 0.58 (0.49-0.69) and NNT was 7 (4.6-8.9); with 1.5 mg·kg, RR was 0.44 (0.33-0.58) and NNT was 5 (3.3-5.2); and with 2 mg·kg, RR was 0.39 (0.24-0.62) and NNT was 3 (2.0-3.4). Adverse effect reporting was sparse. CONCLUSIONS: Within a range of 0.5-2 mg·kg, intravenous lidocaine dose dependently prevents intubation-, extubation-, and opioid-induced cough in adults and children with NNTs ranging from 8 to 3. The risk of harm in high-risk patients remains unknown.
引用
- Clivio S, Putzu A, Tramèr MR, et al. Intravenous Lidocaine for the Prevention of Cough: Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesth Analg. 2019. PMID: 30169416. doi:10.1213/ANE.0000000000003699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。